WCG Launches Neurostatus-eEDSS System
System incorporates Neurostatus Definitions booklet into the electronic data entry process to improve rater accuracy and consistency.
WCG has launched an enhanced digital version of the Neurostatus-Expanded Disability Status Scale (EDSS) to capture clinical trial data. Collaborating with Neurostatus-UHB Ltd., a University Hospital Basel (UHB) subsidiary led by CEO Marcus D'Souza, M.D. and Chief Operating Officer Evy Fricker, the e-EDSS aims to improve data quality for an MS clinical trial endpoint.
While this new system is designed to enhance the rater's data entry experience, it was built to provide better data quality through the implementation of the Neurostatus proprietary scoring algorithms and edit checks, supporting the rater with real-time feedback on data inconsistencies. A web-based data review process has been incorporated into the new e-EDSS system to facilitate faster review and oversight of data quality.
D'Souza said in a press release, "Data entry is extremely fast and easy, given its almost identical replication of the paper form with which researchers are already very familiar. This system also uniquely incorporates the Neurostatus Definitions booklet into the electronic data entry process, and we cannot wait to quantify the direct impact this has on rater accuracy and consistency."
Reference: WCG Collaborates With Leading Multiple Sclerosis KOL to Launch Neurostatus-eEDSS System/PRNewswire
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
